[1] Al Tabaa Y, Bailly C, Kanoun S. FDG-PET/CT in lymphoma: where do we go now?[J] . Cancers (Basel), 2021,13(20):5222.
[2] Chen X, Zhao S, Wang H, et al. Assessment of the prognostic value of interim fluorodeoxy- glucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma[J] . Quant Imaging Med Surg,2021,11(4):1220-1233.
[3] Albano D, Dondi F, Mazzoletti A, et al. Prognostic impact of pretreatment 2-[¹⁸F]-FDG PET/CT parameters in primary gastric DLBCL [J] .Medicina (Kaunas), 2021,57(5):498.
[4] Baratto L, Wu F, Minamimoto R, et al. Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma. [J].Nucl Med Commun, 2021,42(7):792-799.
[5] Cao C, Feng J, Gu H, et al. Distribution of lymphoidneoplasms in Northwest China: analysis of 3244 cases according to WHO classification in a single institution. [J] .Ann Diagn Pathol, 2018, 34: 60-65.
[6] Li H, Shao G, Zhang Y, et al. . Nomograms based on SUVmax of ¹⁸F-FDG PET/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer/T-cell lymphoma[J] .Cancer Imaging,2021,21(1):9.
[7] Wang H, Shen G, Jiang C,et al. Prognostic value of baseline, interim and end-of-treatment ¹⁸F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis. [J].PLoS One, 2018,13(3):e0194435.
[8] Pak K, Kim B S, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis[J].Am J Otolaryngol,2018, 39(1): 1-5.
[9] Guo R, Xu P, Xu H, et al. The predictive value of pre-treatment ¹⁸F-FDG PET/CT on treatment outcome in early-stage extranodal natural killer/T-cell lymphoma[J] .Leuk Lymphoma, 2020, 61 (11): 2659-2664.
[10] Zhu L, Meng Y, Guo L, et al. Predictive value of baseline ¹⁸F-FDG PET/CT and interim treatment response for the prognosis of patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy[J] .Oncol Lett, 2021,21(2):132.
[11] Xie M, Zhai W, Cheng S, et al. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma [J] .Hematology, 2016, 21(2): 99-105.
[12] Gupta N, Singh N. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma) [J] .Nucl Med Commun, 2020,41(4):395-404.
[13] Shagera Q A, Cheon G J, Koh Y, et al. Prognostic value of metabolic tumour volume on baseline ¹⁸F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI[J] .Eur J Nucl Med Mol Imaging, 2019, 46(7):1417-1427.
[14] Toledano M N, Desbordes P, Banjar A, et al. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. [J] .Eur J Nucl Med Mol Imaging, 2018,45(5):680-688.
[15] Chang C C, Cho S F, Chuang Y W, et al. Prognostic significance of total metabolic tumor volume on ¹⁸F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy [J]. Oncotarget, 2017,8(59):99587-99600.
[16] Albano D, Bosio G, Bianchetti N, et al. Prognostic role of baseline ¹⁸F-FDG PET/CT metabolic parameters in mantle cell lymphoma [J] .Ann Nucl Med, 2019,33(7):449-458.
[17] Meignan M, Cottereau A S, Versari A, et al. Baseline metabolic tumor volume predicts out- come in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies [J]. J Clin Oncol, 2016, 34: 3618-3626.
[18] Zhou Y, Zhao Z, Li J, et al. Prognostic values of baseline, interim and end-of therapy F-FDG PET/CT in patients with follicular lymphoma[J] .Cancer Manag Res,2019, 11:6871-6885.
[19] Guo B, Tan X, Ke Q, et al. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis[J]. PLoS ONE. 2019,14(1):e0210224.
[20] Jiang C, Teng Y, Chen J, et al. Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)[J] .EJNMMI Res,2020,10(1):110.
[21] Zhou Y, Zhang X, Qin H, et al. . Prognostic Values of Baseline ¹⁸F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma [J].Biomed Res Int,2020:9746716.
[22] Xia J, Zhu H Y, Liang J H, et al. The prognostic role of ¹⁸F-FDG PET/CT baseline quantitative metabolic parameters in peripheral T-cell lymphoma [J].J Cancer, 2019,10(23): 5805-5811.
[23] Cottereau A S, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial[J].Blood, 2018,131(13): 1456-1463.
[24] Chen X, Zhao S, Wang H, et al. Assessment of the prognostic value of interim fluorodeoxy- glucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma[J].Quant Imaging Med Surg, 2021,11(4):1220-1233.
[25] Qin C, Yang S, Sun X,et al. ¹⁸F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma [J] .Clin Nucl Med, 2019,44(3):201-208.
[26] Jiang C, Liu J, Li L, et al. Predictive approaches for post-therapy PET/CT in patients with extranodal natural killer/T-cell lymphoma: a retrospective study[J].Nucl Med Commun,2017, 38 (11):937-947.
[27] Li X, Sun X, Li J, et al. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma[J].Cancer Med,2019,8(11):5012-5022.
[28] Kitajima K, Okada M, Yoshihara K,et al. Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP[J].Oncotarget, 2019.10(52): 5403-5411.
[29] Jiang M, Chen P, Ruan X, et al. Interim ¹⁸F-FDG PET/CT and BCL2 for predicting the prognosis of patients with diffuse large B-cell lymphoma in the rituximab era [J] .Nucl Med Commun, 2018,39(2):147-153.
[30] Kim J, Lee J O, Paik J H, et al. Different predictive values of interim ¹⁸F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma [J].Ann Nucl Med, 2017,31(1):1-11.
[31] Xie M, Wang L, Jiang Q, et al. Significance of initial, interim and end-of-therapy ¹⁸F-FDG PET/CT for predicting transformation risk in follicular lymphoma[J].Cancer Cell Int, 2021, 21(1): 394.
[32] Boo S H, O J H, Kwon S J, et al. Predictive value of interim and end-of-therapy ¹⁸F-FDG PET/CT in patients with follicular lymphoma[J]. Nucl Med Mol Imaging,2019,53(4):263-269.
[33] El-Galaly T C, Pedersen M B, Hutchings M, et al. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients[J].Am J Hematol,2015, 90 (11):975-980.
[34] Gurion R, Bernstine H, Domachevsky L, et al. Utility of PET-CT for evaluation of patients with peripheral t-cell lymphoma[J] .Clin Lymphoma Myeloma Leuk, 2018,18(10):687-691.
[35] Rossi C, Kanoun S, Berriolo-Riedinger A, et al. Interim ¹⁸F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients[J]. J Nucl Med, 2014, 55(4):569-573.
[36] Trotman J, Barrington SF. The role of PET in first-line treatment of Hodgkin lymphoma.[J] Lancet Haematol, 2021,8(1):e67-e79.